T1	Participants 674 782	AP-1 inhibition on vascular parameters was tested through a double blind placebo-controlled cross-over study
T2	Participants 820 872	patients with symptomatic peripheral artery disease.
T3	Participants 874 924	ascular function was assessed by brachial dilation
